Disorders
Conditions where the myelocyte stage is disrupted: maturation arrest (AML), uncontrolled expansion (CML), left shift, MDS, and congenital granulopoiesis failure.
Cyclic neutropenia maps to ELA2; marrow output oscillates with 21-day periodicity.
Band count of 20 percent or more: 53 percent sensitivity, 79 percent specificity for infection. Limited diagnostic value.
The current classification framework for AML and other myeloid neoplasms.
Serial immature granulocyte counts in critically ill patients associate with mortality.
Places the pro-tumor shift in myeloma at the mature neutrophil, downstream of the precursor stages.
Immature granulocyte count predicts complicated appendicitis.
Review of current AML diagnosis and classification.
Epidemiology and treatment overview. Nothing specific to the myelocyte.
G-CSF from inflamed skin drives pathological granulopoiesis in psoriasis.
Inhaled NO2 causes stage-specific blocks in the granulocytic and erythroid series in mouse marrow.
AI reads genetic complexity and residual marrow composition in acute promyelocytic leukemia, the leukemia arrested at the myelocyte's parent stage.
Letter describing a rare APL variant with basophilic differentiation, the leukemia arrested at the promyelocyte stage upstream of the myelocyte.
Dysbiotic gut microbiota drives neutrophil heterogeneity and NETosis in acute pancreatitis; E. coli is the key driver.
IDH1-R132H mutation represses myeloid progenitor transcriptional programs and blocks differentiation through the myelocyte stage; mechanism: 2-HG-driven epigenetic silencing of C/EBPalpha targets.
TCEA1 (transcription elongation factor A1) activates C/EBPepsilon and IRF8, transcription factors required for the myelocyte-to-neutrophil transition; loss of TCEA1 contributes to APL arrest.
Review: DNA methylation, histone modifications, ncRNA, and m6A mark disturbed granulopoiesis and neutrophil dysfunction in sepsis; epigenetic changes are context-dependent, sometimes antimicrobial, sometimes injurious.
Flumatinib (third-generation BCR-ABL inhibitor) outcomes in chronic myelocytic leukemia, the disease driven by unchecked proliferation of myelocyte-stage precursors.
Comparison of cell-based and bead-based anti-neutrophil antibody assays in pediatric autoimmune neutropenia; pro-LL-37 and ANC thresholds help risk-stratify.
Specific microbial species in occupational bioaerosols drive differential neutrophil inflammatory responses; appeared in scan via granulopoiesis keyword.